Evidence method
Level · gp.fundamentals.debt_to_revenue
184.20% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Mar 31, 2026
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-206546General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.12% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-13.46% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
35.14% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
15.81% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
73.60% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-27.10% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
33.33% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
16.83% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 47.37%
- Current
- 184.20%
- Delta
- 136.83%
- Previous
- 1.07%
- Current
- 1.12%
- Delta
- 0.05%
- Previous
- -16.60%
- Current
- -13.46%
- Delta
- 3.15%
- Previous
- 54.77%
- Current
- 35.14%
- Delta
- -19.63%
- Previous
- 3.55%
- Current
- 15.81%
- Delta
- 12.27%
- Previous
- 74.24%
- Current
- 73.60%
- Delta
- -0.63%
- Previous
- -20.62%
- Current
- -27.10%
- Delta
- -6.47%
- Previous
- 33.85%
- Current
- 33.33%
- Delta
- -0.52%
- Previous
- 18.59%
- Current
- 16.83%
- Delta
- -1.76%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Analogous To · ADPT state analogue 1 →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ADPT CAPEX_INTENSITY_INCREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_DECREASED →Transitioned To · ADPT INVENTORY_PRESSURE_INCREASED →Transitioned To · ADPT MARGIN_DECREASED →Transitioned To · ADPT PROFITABILITY_DECREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.